| Literature DB >> 26504361 |
Shushan Yan1, Pengjun Zhang2, Wei Xu3, Yuqing Liu4, Bin Wang5, Tao Jiang6, Changjiang Hua6, Xuan Wang6, Donghua Xu7, Beicheng Sun8.
Abstract
SUA is a potent antioxidant and thus may play a protective role against cancer. Many epidemiological studies have investigated this hypothesis but provided inconsistent and inconclusive findings. We aimed to precisely elucidate the association between SUA levels and cancer by pooling all available publications. Totally, 5 independent studies with 456,053 subjects and 12 with 632,472 subjects were identified after a comprehensive literature screening from PubMed, Embase, and Web of Science. The pooled RRs showed that individuals with high SUA levels were at an increased risk of total cancer incidence (RR = 1.03, 95% CI 1.01-1.05, P = 0.007). Positive association between high SUA levels and total cancer incidence was observed in males but not females (for men: RR = 1.05, 95% CI 1.02-1.08, P = 0.002; for women, RR = 1.01, 95% CI 0.98-1.04, P = 0.512). Besides, high SUA levels were associated with an elevated risk of total cancer mortality (RR = 1.17, 95% CI 1.04-1.32, P = 0.010), particularly in females (RR = 1.25, 95% CI 1.07-1.45, P = 0.004). The study suggests that high SUA levels increase the risk of total cancer incidence and mortality. The data do not support the hypothesis of a protective role of SUA in cancer.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26504361 PMCID: PMC4609511 DOI: 10.1155/2015/764250
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Characteristics of all studies.
| First author | Year | Study design | Origins | Sample size | Followup (years) | Baseline time | Sex | Cancer |
|---|---|---|---|---|---|---|---|---|
| Cancer incidence | ||||||||
| Horsfall [ | 2014 | Prospective cohort study | UK | 205,484 | 5 | 2000–2012 | Mixed | Lung |
| Strasak [ | 2009 | Prospective cohort study | Austrian | 78,850 | 12.4 | 1985–2003 | Men | All |
| Kolonel [ | 1994 | Prospective cohort study | Hawaii | 7,889 | 27 | 1965–1968 | Men | All |
| Hiatt [ | 1988 | Prospective cohort study | USA | 75,283 | 9.8 | 1965–1972 | Men | All |
| Hiatt [ | 1988 | Prospective cohort study | USA | 88,547 | 9.8 | 1965–1972 | Women | All |
| Cancer mortality | ||||||||
| Taghizadeh [ | 2014 | Prospective cohort study | Dutch | 4,350 | 38 | 1965–1969 | Men | All |
| Juraschek [ | 2014 | Prospective cohort study | Scotland | 15,083 | 22.7 | 1984–1987 | Mixed | All |
| Kuo [ | 2013 | Prospective cohort study | Taiwan | 354,110 | 9 | 2000–2007 | Mixed | All |
| Strasak [ | 2007 | Prospective cohort study | Austrian | 28,613 | 15.2 | 1985–2005 | Women | All |
| Strasak [ | 2007 | Prospective cohort study | Austrian | 83,683 | 13.6 | 1985–2005 | Men | All |
| Jee [ | 2004 | Prospective cohort study | Korean | 22,698 | 9 | 1992–1996 | Men | All |
| Colangelo [ | 2002 | Prospective cohort study | USA | 20,433 | 26.2 | 1967–1973 | Men | Colorectal cancer |
| Colangelo [ | 2002 | Prospective cohort study | USA | 15,149 | 26.2 | 1967–1973 | Women | Colorectal cancer |
| Tomita [ | 2000 | Prospective cohort study | Japanese | 49,413 | 5.4 | 1975–1982 | Men | All |
| Gapstur [ | 2000 | Prospective cohort study | USA | 20,475 | 25 | 1963–1973 | Men | Pancreatic cancer |
| Gapstur [ | 2000 | Prospective cohort study | USA | 15,183 | 25 | 1963–1973 | Women | Pancreatic cancer |
| Mazza [ | 1999 | Prospective cohort study | Italy | 3,282 | 12 | Not reported | Mixed | All |
Summary meta-analysis results for the association between SUA levels and cancer.
| Group/subgroup | Number | RR (95% CI) |
|
|
|
|---|---|---|---|---|---|
| Cancer incidence | |||||
| All | 456,053 | 1.03 (1.01–1.05) | 0.007 | 44.7 | 0.124 |
| Men | 162,022 | 1.05 (1.02–1.08) | 0.002 | 53.8 | 0.115 |
| Women | 88,547 | 1.01 (0.98–1.04) | 0.512 | — | — |
| Specific sites | |||||
| Any | 250,569 | 1.03 (1.01–1.05) | 0.006 | 57.9 | 0.068 |
| Respiratory system and intrathoracic organs | 456,053 | 1.05 (0.93–1.19) | 0.448 | 67.5 | 0.015 |
| Digestive organs | 266,347 | 1.08 (0.94–1.25) | 0.263 | 63.4 | 0.018 |
| Urinary organs | 86,739 | 1.17 (0.44–3.15) | 0.752 | 82.3 | 0.018 |
| Lymphoid and hematopoietic systems | 86,739 | 1.71 (1.10–2.68) | 0.018 | 30.0 | 0.232 |
| Male genital organs | 162,022 | 1.06 (1.00–1.13) | 0.058 | 56.1 | 0.103 |
| Cancer mortality | |||||
| All | 632,472 | 1.17 (1.04–1.32) | 0.010 | 65.8 | 0.001 |
| Men | 201,052 | 1.13 (0.86–1.48) | 0.384 | 77.5 | <0.001 |
| Women | 58,945 | 1.25 (1.07–1.45) | 0.004 | 30.0 | 0.240 |
| Specific sites | |||||
| Any | 561,232 | 1.17 (1.04–1.32) | 0.011 | 70.7 | 0.001 |
| Respiratory system and intrathoracic organs | 116,646 | 1.08 (0.61–1.91) | 0.786 | 78.2 | 0.010 |
| Digestive organs | 187,886 | 1.27 (1.08–1.49) | 0.003 | 40.1 | 0.124 |
| Urinary organs | 112,296 | 1.35 (0.88–2.07) | 0.172 | 0.0 | 0.681 |
| Lymphoid and hematopoietic systems | 112,296 | 1.18 (0.82–1.70) | 0.364 | 0.0 | 0.837 |
| Bone, connective tissue, soft tissue, and skin | 112,296 | 0.94 (0.47–1.87) | 0.857 | 0.0 | 0.588 |
| Male genital organs | 88,033 | 0.51 (0.07–3.85) | 0.516 | 75.5 | 0.044 |
Figure 1(a) Forest plot for SUA and the risk of cancer incidence; (b) forest plot for SUA and the risk of cancer mortality; (c) Begg's funnel plots for the risk of cancer incidence (P value for Egger's test equal to 0.295); (d) Begg's funnel plots for the risk of cancer mortality (P value for Egger's test equal to 0.354).